Related Experiment Video
Updated: Mar 1, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Challenges in the delivery of therapies to melanoma brain metastases
Gautham Gampa1, Shruthi Vaidhyanathan1, Brynna-Wilken Resman1
1Brain Barriers Research Center, Department of Pharmaceutics, University of Minnesota, Minneapolis, Minnesota, USA.
Abstract:
Brain metastases are a major cause of morbidity and mortality in patients with advanced melanoma. Recent approval of several molecularly-targeted agents and biologics has brought hope to patients with this previously untreatable disease. However, patients with symptomatic melanoma brain metastases have often been excluded from pivotal clinical trials. This may be in part attributed to the fact that several of the approved small molecule molecularly-targeted agents are substrates for active efflux at the blood-brain barrier, limiting their effective delivery to brain metastases. We believe that successful treatment of melanoma brain metastases will depend on the ability of these agents to traverse the blood-brain barrier and reach micrometastases that are often not clinically detectable. Moreover, overcoming the emergence of a unique pattern of resistance, possibly through adequate delivery of combination targeted therapies in brain metastases will be important in achieving a durable response. These concepts, and the current challenges in the delivery of new treatments to melanoma brain metastases, are discussed in this review.
Insights
Effective treatment for melanoma brain metastases requires targeted therapies that cross the blood-brain barrier. Overcoming resistance through combination therapies is crucial for durable responses in patients with brain metastases.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Melanoma brain metastases significantly increase morbidity and mortality.
- Recent targeted therapies offer hope but face delivery challenges.
- Patients with symptomatic brain metastases are often excluded from clinical trials.
Purpose of the Study:
- To review challenges in delivering targeted therapies to melanoma brain metastases.
- To discuss strategies for overcoming blood-brain barrier limitations.
- To explore overcoming resistance mechanisms for durable responses.
Main Methods:
- Review of current literature on melanoma brain metastases treatment.
- Analysis of molecularly-targeted agents and their blood-brain barrier penetration.
- Discussion of resistance patterns and combination therapy approaches.
Main Results:
- Many targeted agents are effluxed at the blood-brain barrier, limiting efficacy.
- Effective delivery to micrometastases is essential for successful treatment.
- Emergence of resistance is a significant challenge in brain metastases.
Conclusions:
- Successful treatment hinges on agents that can cross the blood-brain barrier.
- Combination targeted therapies are necessary to overcome resistance.
- Addressing delivery challenges is key to improving outcomes for melanoma brain metastases.
